Neurol. praxi, 2012; 13(Suppl.E)

Pathophysiology of diabetic neuropathy

MUDr.Rudolf Kotas, Ph.D., prof.MUDr.Zdeněk Ambler, DrSc.
Neurologická klinika LF UK a FN Plzeň

The pathophysiology of diabetic peripheral neuropathy (DPN) is multifactorial and both vascular factors with impairment of vasa nervorum

and metabolic interactions are involved at all stages of DPN. The complex and interrelated effects of hyperglycemia include increased

metabolic flux through the polyol pathway with consequent sorbitol and fructose accumulation, reduced myoinositol and sodium-potassium

ATPase levels and altered protein kinase C activity. Accumulation of advanced glycation end-products, increased reactive oxygen

species, altered omega-6-essential fatty acids metabolism and deficit of neurotrophic factors compromise both endoneurial microvessels

and neural tissues, accelerate neuronal apoptosis and increase oxidative stress. Immunological alterations and changes in blood flow

have an influence on the nerve pathology. Vascular risk factors are also important contributors to the development of DPN.

Keywords: oxidative stress, polyol pathway, advanced glycation, omega-6-essential fatty acids, neurotrophic factors, immune mechanisms, dyslipidemia

Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kotas R, Ambler Z. Pathophysiology of diabetic neuropathy. Neurol. praxi. 2012;13(Suppl.E):.
Download citation

References

  1. Asbury AK, Aldredge H, Hershberg R, Fisher CM. Oculomotor palsy in diabetes mellitus: a clinico-pathological study. Brain 1970; 93: 955-966. Go to original source... Go to PubMed...
  2. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies. Diabetes Care 2004; 27: 1458-1486. Go to original source... Go to PubMed...
  3. Figueroa-Romeo C, Sadidi M, Feldman EL. Mechanisms of disease: The oxidative stress theory of diabetic neuropathy. Rev Endocr Metab Disord 2008; 9: 301-314. Go to original source... Go to PubMed...
  4. Jack MM, Wright DE. Role of advanced glycation endproducts and glyoxalase I in diabetic peripheral sensory neuropathy. Trans Res 2012; 159: 355-365. Go to original source... Go to PubMed...
  5. Kim HC, Cho YJ, Ahn CW, Park KS, Kim JC, Nam JS, Im YS, Lee JE, Lee SC, Lee HK. Nerve growth factor and expression of its receptors in patients with diabetic neuropathy. Diabet Med 2009; 26: 1228-1234. Go to original source... Go to PubMed...
  6. Krahulec B. Patogenéza diabetickej neuropatie. In: Krahulec B, Žúži M, Vozár J, Kučera P, Mazárová V. Diabetická polyneuropatia. Bratislava: Lufema, 1999: 11-18.
  7. Leinninger GM, Edwards JL, Lipshaw MJ, Feldman EL. Mechanisms of disease: mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Prac 2006; 2: 620-628. Go to original source... Go to PubMed...
  8. Low PA, Nickander KK, Scionti L. Role of hypoxia, oxidative stress, and excitatory neurotoxins in diabetic neuropathy. In: Dyck PJ, Thomas PK. Diabetic Neuropathy (2nd ed). Philadelphia: W.B. Saunders Company, 1999: 317-329.
  9. Mazárová V, Bouček P. Diabetická neuropatie. In: Bartoš V, Pelikánová T. Praktická diabetologie (3. vyd.). Praha: Maxdorf, 2003. 259-270.
  10. Oates PJ. Aldose reductase, still a compelling target for diabetic neuropathy. Curr Drug Targets 2008; 9: 14-36. Go to original source... Go to PubMed...
  11. Said G, Lacroix C, Lozeron P, Ropert A, Planté V, Adams D. Inflammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003; 126: 376-385. Go to original source... Go to PubMed...
  12. Shakher J, Stevens M. Update on the management of diabetic polyneuropathies. Diabetes Metab Syndr Obes 2011; 4: 289-305. Go to original source...
  13. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001; 44: 129-146. Go to original source... Go to PubMed...
  14. Škrha J. Patofyziologie a patogeneze diabetické polyneuropatie. Vnitř Lék 2005; 51: S29-S34.
  15. Tesfaye S, Malik RA, Harris N, Jakubovski JJ, Mody C, Rennie IG, Ward JD. Arterio-venous shunting and proliferating new vessels in acute painful neuropathy of rapid glycemic control (insulin neuritis). Diabetologia 1996; 39: 329-335. Go to original source... Go to PubMed...
  16. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev 2012; 28(Suppl 1): 8-14. Go to original source... Go to PubMed...
  17. Thaisetthawatkul P, Dyck PJ. Treatment of diabetic and nondiabetic lumbosacral radiculoplexus neuropathy. Curr Treat Option N 2010; 12: 95-99. Go to original source... Go to PubMed...
  18. Vincent AM, Hinder LM, Pop-Busui R, Feldman EL. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Sys 2009; 14: 257-267. Go to original source... Go to PubMed...
  19. Vinik AI. Advances in diabetes for the millenium: New treatments for diabetic neuropathies. Med Gen Med 2004; 6(Suppl 3): 1-7.
  20. Walkins PJ, Thomas PK. Diabetic Truncal radiculoneuropathy. In: Dyck PJ, Thomas PK. Diabetic Neuropathy (2nd ed.). Philadelphia: W.B. Saunders Comapny, 1994: 68-473.
  21. Wilbourn AJ. Diabetic entrapment and compression neuropathies. In: Dyck PJ, Thomas PK. Diabetic Neuropaty (2nd Ed.). Philadelphia: W.B. Saunders Company, 1999: 481-508.
  22. Yagihashi S, Mizukami H, Sugimoto K. Mechanism of diabetic neuropathy: Where are we now and where to go? J Diabetes Invest 2011; 2: 18-32. Go to original source... Go to PubMed...
  23. Ziegler D, Nowak H, Kemplert P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a metaanalysis. Diabet Med 2004; 21: 114-121. Go to original source... Go to PubMed...
  24. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. How far have we come? Diabetes Care 2008; 31(Suppl 2): S255-S261.




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.